Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | MC4R | P32245 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631202 | 1.00 | CYP2D6 (0.73) | CYP2D6MC4RALDH1A1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL28177303 | 0.98 | CYP2D6 (0.70) | CYP2D6MC4RALDH1A1CYP3A4TSHR | |
| SCHEMBL6706135 | 0.85 | CYP2D6 (1.00) | CYP2D6MC4RALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL7264542 | 0.85 | CYP2D6 (1.00) | CYP2D6MC4RALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL16226061 | 0.85 | CYP2D6 (1.00) | CYP2D6MC4RALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL23850144 | 0.81 | CYP2D6 (0.83) | CYP2D6MC4RALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL30364156 | 0.81 | CYP2D6 (0.83) | CYP2D6MC4RALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL8983562 | 0.81 | CYP2D6 (0.83) | CYP2D6MC4RALDH1A1CYP3A4TSHR | |
| SCHEMBL8983627 | 0.81 | CYP2D6 (0.83) | CYP2D6MC4RALDH1A1CYP3A4TSHR | |
| SCHEMBL7097730 | 0.81 | CYP2D6 (0.83) | CYP2D6MC4RALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| US-8993561-B2 | Nitrobenzothiazole derivatives, preparation thereof and therapeutic applications thereof | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8993561-B2 | Nitrobenzothiazole derivatives, preparation thereof and therapeutic applications thereof | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8895781-B2 | Transition metal-catalyzed C—H amination using unactivated amines | GEORGETOWN UNIVERSITY (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895781-B2 | Transition metal-catalyzed C—H amination using unactivated amines | GEORGETOWN UNIVERSITY (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2643307-B1 | NITROBENZOTHIAZOLE DERIVATIVES AND USE THEREOF FOR TREATING TUBERCULOSIS | SANOFI SA (FR) | 2014-09-17 | — | — | EP | disclosed |
| US-20130245008-A1 | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| US-20130245008-A1 | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069743-A1 | NITROBENZOTHIAZOLE DERIVATIVES AND USE THEREOF FOR TREATING TUBERCULOSIS | SANOFI (FR) | 2012-05-31 | — | — | WO | disclosed |
| EP-2379521-A1 | SULFAMIDES AS TRPM8 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110213146-A1 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines | GEORGETOWN UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213146-A1 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines | GEORGETOWN UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2010080397-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010028159-A2 | TRANSITION METAL-CATALYZED C-H AMINATION USING UNACTIVATED AMINES | GEORGETOWN UNIVERSITY (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245008-A1 | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF | NDUFB7, NDUFB3, SDHB | CYP2D6 372/4885MC4R 2734/4885ALDH1A1 488/4885 |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | CYP2D6 1759/4885MC4R 2888/4885ALDH1A1 144/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | CYP2D6 981/4885MC4R 2121/4885ALDH1A1 89/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | CYP2D6 1759/4885MC4R 2888/4885ALDH1A1 144/4885 |
| US-20110213146-A1 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines | AOC3, AOC2, MPO | CYP2D6 1764/4885MC4R 1957/4885ALDH1A1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.